Recent next-step advances in cancer immunology are found on many frontiers: on targeting cancer and cancer niches with specific conjugated or unconjugated monoclonal antibodies, by activating immune responses via monoclonal antibodies, antigens and vaccines, cytokines, costimulatory pathways, and checkpoint modulators, or by adoptive cell transfer, comprising the newly approved CAR T biomedicines, and many combinatorial strategies for an increasing number of sub-indications. The field has quickly carved out a new 50-billion-dollar biologics industry that is expected to double again in only 4-5 years.
ALSO READ : http://www.marketwatch.com/story/cancer-immunotherapy-market-resear...
Conventional cancer treatments are still the most practiced and the most canonical therapies of today`s medical anti-cancer strategies. They comprise surgery, chemotherapy, and radiation therapy, while cancer immunotherapy is still the new approach that is further becoming further becoming increasingly accepted and has only recently been innovated and approved. In early 2018, approximately 32 monoclonal antibodies were approved by the FDA or EMA for cancer immunotherapy for a cancer indication and medical purpose. There are more than 10,000 clinical studies linked to these 32 medicinal products of the biologics type, which are registered at the NIH and at the NIH database.
In 2016, immunotherapy treatments captured 33% of spending on oncology drugs, despite accounting for just 9% of FDA-approved oncology drugs. All the large oncology drug companies are building robust immunotherapy pipelines, driving increased M&A and investor interest.
ALSO READ : http://www.marketwatch.com/story/braiding-machinery-market-research...
Based on therapy, the market is fragmented into monoclonal antibodies, vaccines, checkpoint inhibitors, cell therapies, immune system modulators, adoptive cell transfer, cytokines, and others. The monoclonal antibodies segment generated revenue of USD 32.57 billion in 2020. The market is expected to grow at a CAGR of 10.29% during the forecast period to reach a market valuation of USD 65.13 billion by 2027F owing to the diverse set of clinically relevant mechanisms of action like directly targeting tumor cells while simultaneously promoting the induction of long-lasting anti-tumor immune responses.
Based on the application, the market is fragmented into lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head and neck cancer, other cancer applications. The lung segment dominated the market and generated revenue of USD 22.26 billion in 2020. However, breast cancer is anticipated to grow at the highest CAGR during the forecast period and reach USD 36.10 billion by 2027F.
The cancer immunotherapies are available at various centres including Cancer specialty/research centres and hospitals & clinics. The cancer specialty/research centres are anticipated to dominate the market during the analyzed period and reach USD 111.65 billion by 2027F. Also, the segment is expected to grow at the highest CAGR throughout the forecast period 2021-2027F.
ALSO READ : http://www.marketwatch.com/story/outdoor-furniture-and-grill-market...
For a better understanding of the market adoption of the Cancer Immunotherapy market, the market is analyzed based on its worldwide presence in the countries such as North America (United States and Canada), Europe (Germany, France, Italy, Spain, United Kingdom and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of APAC), and Rest of World. North America constitutes a major market for the Cancer Immunotherapy industry and generated revenue of USD 37.56 billion in 2020 owing to the increasing incidence of cancer, and rising healthcare spending in the region.
Some of the major players operating in the market include AbbVie, Amgen, AstraZeneca, bluebird bio, Bristol-Myers Squibb, F. Hoffmann-La Roche, Janssen Biotech, Merck, Novartis, and Pfizer. Several M&A’s along with partnerships have been undertaken by these players to develop Cancer Immunotherapy.
The global Cancer Immunotherapy market was valued at USD 87.40 billion in 2020 and is projected to expand significantly with a CAGR of 10.25% from 2021-2027F. The market is expected to witness a boost on Increasing patient pool and higher mortality rate are augmenting the need for cancer immunotherapy globally.
Table of Contents
1 MARKET INTRODUCTION
1.1 Market Definitions
1.2 Objective of the Study
1.3 Limitation
1.4 Stake Holders
1.5 Currency Used in Report
1.6 Scope of the Global Cancer Immunotherapy Market Study
2 RESEARCH METHODOLOGY OR ASSUMPTION
2.1 Research Methodology for the Global Cancer Immunotherapy Market
2.1.1 Main Objective of the Global Cancer Immunotherapy Market
3 MARKET SYNOPSIS
4 EXECUTIVE SUMMARY
5 TOP START-UPS UNDER CANCER IMMUNOTHERAPY SECTOR
6 CANCER IMMUNOTHERAPY AMID COVID-19
7 GLOBAL CANCER IMMUNOTHERAPY MARKET REVENUE (USD BN), 2019-2027F
8 MARKET INSIGHTS BY THERAPY
8.1 Monoclonal Antibodies
8.2 Vaccines
8.3 Checkpoint Inhibitors
8.4 Cell Therapies
8.5 Immune System Modulators
8.6 Adoptive Cell Transfer
8.7 Cytokines
8.8 Others
9 MARKET INSIGHTS BY APPLICATION
9.1 Lung Cancer
9.2 Breast Cancer
9.3 Colorectal Cancer
9.4 Melanoma
9.5 Prostate Cancer
9.6 Head and Neck Cancer
9.7 Other Cancer Applications
10 MARKET INSIGHTS BY END-USER
10.1 Cancer Specialty/Research Centers
10.2 Hospitals & Clinics
11 MARKET INSIGHTS BY REGION
11.1 North America Cancer Immunotherapy Market
11.1.1 United States
11.1.2 Canada
11.2 Europe Cancer Immunotherapy Market
11.2.1 Germany
11.2.2 France
11.2.3 United Kingdom
11.2.4 Italy
11.2.5 Spain
11.2.6 Rest of Europe
11.3 Asia Pacific Cancer Immunotherapy Market
11.3.1 China
11.3.2 Japan
11.3.3 India
11.3.4 Australia
11.3.5 Rest of Asia Pacific
11.4 Rest of World Cancer Immunotherapy Market
12 CANCER IMMUNOTHERAPY MARKET DYNAMICS
12.1 Market Drivers
12.2 Market Challenges
12.3 Impact Analysis
13 CANCER IMMUNOTHERAPY MARKET OPPORTUNITIES
14 CANCER IMMUNOTHERAPY MARKET TRENDS
15 LEGAL & REGULATORY FRAMEWORK
16 DEMAND AND SUPPLY SIDE ANALYSIS
16.1 Demand Side Analysis
16.2 Supply Side Analysis
16.2.1 Top Product Launches
16.2.2 Top Business Partnerships
16.2.3 Top Business Expansions, Investments and Divestitures
16.2.4 Top Merger and Acquisitions
17 VALUE CHAIN ANALYSIS
18 COMPETITIVE SCENARIO
18.1 Porter’s Five Forces Analysis
18.1.1 Bargaining power of Supplier
18.1.2 Bargaining power of Buyer
18.1.3 Industry Rivalry
18.1.4 Availability of Substitute
18.1.5 Threat of new Entrants
18.2 Competitive Landscape
18.2.1 Company Shares, By Revenue
19 COMPANY PROFILED
19.1 AbbVie
19.2 Amgen
19.3 AstraZeneca
19.4 bluebird bio
19.5 Bristol-Myers Squibb
19.6 F Hoffmann-La Roche
19.7 Janssen Biotech
19.8 Merck
19.9 Novartis
19.10 Pfizer
20 DISCLAIMER----
..…..continued
CONTACT DETAILS :
[email protected]
+44 203 500 2763
+1 62 825 80070
971 0503084105